Study wrapper · #1056
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
Editor's note
A phase 3b randomized trial reporting that adding once-weekly semaglutide while reducing basal insulin outperformed titrating insulin alone on glycemic control, weight, and insulin dose, with fewer severe hypoglycemia events. The open-label design is a limitation, and gastrointestinal events were notably higher in the semaglutide arm. Readers can read the results as consistent with the broader SUSTAIN evidence base for semaglutide in type 2 diabetes.
Plain-language abstract
In this 40-week randomized trial of 573 adults with type 2 diabetes and overweight, once-weekly semaglutide 2.0 mg added to a reduced insulin glargine dose was associated with greater reductions in HbA1c, body weight, and daily insulin need than up-titrated insulin alone. Severe low-blood-sugar events were less frequent in the semaglutide arm, though gastrointestinal side effects were more common.